[go: up one dir, main page]

IN2014DN09787A - - Google Patents

Info

Publication number
IN2014DN09787A
IN2014DN09787A IN9787DEN2014A IN2014DN09787A IN 2014DN09787 A IN2014DN09787 A IN 2014DN09787A IN 9787DEN2014 A IN9787DEN2014 A IN 9787DEN2014A IN 2014DN09787 A IN2014DN09787 A IN 2014DN09787A
Authority
IN
India
Prior art keywords
delta
cells expressing
methods
cultured
present disclosure
Prior art date
Application number
Inventor
Thomas M Schmitt
Philip D Greenberg
Original Assignee
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchinson Fred Cancer Res filed Critical Hutchinson Fred Cancer Res
Publication of IN2014DN09787A publication Critical patent/IN2014DN09787A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/065—Thymocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1394—Bone marrow stromal cells; whole marrow
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)

Abstract

The present disclosure provides methods for generating enhanced affinity T cell receptors by agonist selection of hematopoietic progenitor cells expressing an antigen specific TCRa cultured with stromal cells expressing Delta-like-1 or Delta-like 4, compositions prepared from such methods, and uses of thereof.
IN9787DEN2014 2012-05-03 2014-11-19 IN2014DN09787A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642358P 2012-05-03 2012-05-03
PCT/US2013/039316 WO2013166321A1 (en) 2012-05-03 2013-05-02 Enhanced affinity t cell receptors and methods for making the same

Publications (1)

Publication Number Publication Date
IN2014DN09787A true IN2014DN09787A (en) 2015-07-31

Family

ID=49514896

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9787DEN2014 IN2014DN09787A (en) 2012-05-03 2014-11-19

Country Status (17)

Country Link
US (2) US9751928B2 (en)
EP (1) EP2844743B1 (en)
JP (2) JP6251734B2 (en)
KR (2) KR102276888B1 (en)
CN (2) CN107557334B (en)
AU (2) AU2013256159B2 (en)
BR (1) BR112014027374B1 (en)
CA (1) CA2872471C (en)
ES (1) ES2858248T3 (en)
IL (1) IL235355B (en)
IN (1) IN2014DN09787A (en)
MX (1) MX361760B (en)
NZ (1) NZ702108A (en)
PH (1) PH12014502418B1 (en)
RU (2) RU2665548C2 (en)
SG (2) SG11201407175RA (en)
WO (1) WO2013166321A1 (en)

Families Citing this family (294)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006304573B2 (en) 2005-10-17 2012-05-24 Sloan Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
JP2009511081A (en) 2005-10-18 2009-03-19 ナショナル ジューイッシュ メディカル アンド リサーチ センター Conditionally immortalized long-term stem cells and methods of making and using such cells
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
KR101803099B1 (en) 2008-05-16 2017-11-30 타이가 바이오테크놀로지스, 인코포레이티드 Antibodies and processes for preparing the same
JP5812861B2 (en) 2008-08-28 2015-11-17 タイガ バイオテクノロジーズ，インク． MYC modifier, method of using the MYC modifier, and method of identifying agents that modulate MYC
EP3520810A3 (en) 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Immunogenic wt1 peptides and use thereof
CA2879667C (en) 2012-07-20 2021-11-16 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide
EP3653212B1 (en) 2012-12-20 2023-04-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
WO2014113490A2 (en) 2013-01-15 2014-07-24 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
SG10201804330YA (en) * 2013-11-22 2018-07-30 Univ Illinois Engineered high-affinity human t cell receptors
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
AU2014368898B2 (en) 2013-12-20 2020-06-11 Dana-Farber Cancer Institute, Inc. Combination therapy with neoantigen vaccine
AU2015289644A1 (en) 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
CN107074970B (en) * 2014-08-04 2021-07-30 弗雷德哈钦森癌症研究中心 T cell immunotherapy specific for WT-1
TWI751102B (en) 2014-08-28 2022-01-01 美商奇諾治療有限公司 Antibodies and chimeric antigen receptors specific for cd19
SG11201703203RA (en) 2014-10-20 2017-05-30 Juno Therapeutics Inc Methods and compositions for dosing in adoptive cell therapy
ES2805674T3 (en) 2014-11-05 2021-02-15 Juno Therapeutics Inc Methods for cell transduction and processing
CN107206025A (en) 2014-12-03 2017-09-26 朱诺治疗学股份有限公司 The method and composition treated for adoptive cellular
ES3049406T3 (en) 2014-12-19 2025-12-16 Broad Inst Inc Methods for profiling the t-cell-receptor repertoire
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
MA41346A (en) 2015-01-12 2017-11-21 Juno Therapeutics Inc POST-TRANSCRIPTIONAL REGULATORY ELEMENTS OF MODIFIED HEPATITIS
AR103442A1 (en) 2015-01-16 2017-05-10 Juno Therapeutics Inc ANTIBODIES AND RECEIVERS OF SPECIFIC CHEMICAL ANTIGENS OF ROR1
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc Shared neoantigens
AU2016271147B2 (en) 2015-05-29 2022-09-08 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
AU2016279062A1 (en) 2015-06-18 2019-03-28 Omar O. Abudayyeh Novel CRISPR enzymes and systems
MA42895A (en) 2015-07-15 2018-05-23 Juno Therapeutics Inc MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
CN108289954B (en) 2015-09-24 2022-05-31 阿布维特罗有限责任公司 HIV antibody compositions and methods of use
CN108369230B (en) 2015-09-25 2021-09-17 阿布维特罗有限责任公司 High throughput method for T cell receptor targeted identification of naturally paired T cell receptor sequences
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
JP7195141B2 (en) 2015-10-22 2022-12-23 ジュノ セラピューティクス ゲーエムベーハー Methods, kits, agents and devices for transduction
MA45489A (en) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh CELL CULTURE PROCESSES, ASSOCIATED KITS AND APPARATUS
MA45488A (en) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh CELL CULTURE PROCESSES, KITS AND APPARATUS
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
EP3368689B1 (en) 2015-10-28 2020-06-17 The Broad Institute, Inc. Composition for modulating immune responses by use of immune cell gene signature
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
MA44314A (en) 2015-11-05 2018-09-12 Juno Therapeutics Inc CHEMERICAL RECEPTORS CONTAINING TRAF-INDUCING DOMAINS, AND ASSOCIATED COMPOSITIONS AND METHODS
CA3005878A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
ES2928167T3 (en) 2015-12-03 2022-11-15 Juno Therapeutics Inc Compositions and methods for reducing immune responses against chimeric antigen receptors
CN108884140B (en) 2015-12-03 2022-10-25 朱诺治疗学股份有限公司 Modified chimeric receptors and related compositions and methods
ES2901795T3 (en) 2015-12-04 2022-03-23 Juno Therapeutics Inc Methods and compositions related to toxicity associated with cell therapy
WO2017112944A1 (en) * 2015-12-23 2017-06-29 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
US20190287013A1 (en) 2016-03-16 2019-09-19 Juno Therapeutics, Inc. Methods for determining dosing of a therapeutic agent and related treatments
US20190355459A1 (en) 2016-03-16 2019-11-21 Juno Therapeutics, Inc. Methods for adaptive design of a treatment regimen and related treatments
RU2018136877A (en) 2016-03-22 2020-04-22 СИЭТЛ ЧИЛДРЕН'С ХОСПИТАЛ (ДиБиЭй СИЭТЛ ЧИЛДРЕН'С РИСЕРЧ ИНСТИТЬЮТ) WAYS OF EARLY INTERVENTION FOR PREVENTION OR IMPROVEMENT OF TOXICITY
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
KR20230038299A (en) 2016-05-06 2023-03-17 주노 쎄러퓨티크스 인코퍼레이티드 Genetically engineered cells and methods of making the same
EP3452514A1 (en) 2016-05-06 2019-03-13 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for mart-1
MX388294B (en) 2016-05-27 2025-03-19 Aadigen Llc PEPTIDES AND NANOPARTICLES FOR INTRACELLULAR DELIVERY OF GENOME EDITING MOLECULES.
EP4011381A1 (en) 2016-06-03 2022-06-15 Memorial Sloan-Kettering Cancer Center Adoptive cell therapies as early treatment options
MA45341A (en) 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res METHODS FOR TREATING B-LYMPHOCYTE MALIGNITIES USING ADOPTIVE CELL THERAPY
MA45491A (en) 2016-06-27 2019-05-01 Juno Therapeutics Inc CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
EP3475446A1 (en) 2016-06-27 2019-05-01 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
US11421287B2 (en) 2016-07-29 2022-08-23 Juno Therapeutics, Inc. Methods for assessing the presence or absence of replication competent virus
ES3004039T3 (en) 2016-07-29 2025-03-11 Juno Therapeutics Inc Anti-idiotypic antibodies against anti-cd19 antibodies
MA45779A (en) 2016-07-29 2019-06-05 Juno Therapeutics Inc POLYPEPTIDES IMMUNOMDULATORS AND RELATED COMPOSITIONS AND PROCESSES
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
JP2019526269A (en) 2016-09-12 2019-09-19 ジュノー セラピューティクス インコーポレイテッド Perfusion bioreactor bag assembly
CN110087657A (en) 2016-09-28 2019-08-02 阿托莎遗传股份有限公司 The method of adoptive cellular treatment
US12499971B2 (en) 2016-09-28 2025-12-16 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
US11072660B2 (en) 2016-10-03 2021-07-27 Juno Therapeutics, Inc. HPV-specific binding molecules
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
US11896615B2 (en) 2016-10-13 2024-02-13 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
WO2018093591A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
MA46783A (en) 2016-11-03 2019-09-11 Juno Therapeutics Inc T-CELL THERAPY AND BTK INHIBITOR POLYTHERAPY
WO2018089386A1 (en) 2016-11-11 2018-05-17 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
AU2017356322B2 (en) 2016-11-14 2023-09-21 Fred Hutchinson Cancer Center High affinity merkel cell polyomavirus T antigen-specific TCRs and uses thereof
WO2018102678A1 (en) 2016-12-02 2018-06-07 Taiga Biotechnologies, Inc. Nanoparticle formulations
US11590167B2 (en) 2016-12-03 2023-02-28 Juno Therapeutic, Inc. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
ES2961666T3 (en) 2016-12-03 2024-03-13 Juno Therapeutics Inc Methods to determine CAR-T cell dosage
BR112019011025A2 (en) 2016-12-03 2019-10-08 Juno Therapeutics Inc T cell modulation methods
JP2019536461A (en) 2016-12-05 2019-12-19 ジュノー セラピューティクス インコーポレイテッド Production of engineered cells for adoptive cell therapy
EP3568414A1 (en) 2017-01-10 2019-11-20 Juno Therapeutics, Inc. Epigenetic analysis of cell therapy and related methods
WO2018134691A2 (en) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2018148671A1 (en) 2017-02-12 2018-08-16 Neon Therapeutics, Inc. Hla-based methods and compositions and uses thereof
BR112019017120A8 (en) 2017-02-17 2023-05-02 Hutchinson Fred Cancer Res COMBINATION THERAPIES FOR TREATMENT OF CANCER AND BCMA-RELATED AUTOIMMUNE DISORDERS
CN110582287A (en) 2017-02-27 2019-12-17 朱诺治疗学股份有限公司 Compositions, articles of manufacture and methods related to administration in cell therapy
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
EA201992155A1 (en) 2017-03-14 2020-03-16 Джуно Терапьютикс, Инк. METHODS OF CRYOGENIC STORAGE
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
WO2018183921A1 (en) 2017-04-01 2018-10-04 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2018187356A2 (en) 2017-04-03 2018-10-11 Neon Therapeutics, Inc. Protein antigens and uses thereof
US20230190796A1 (en) 2017-04-07 2023-06-22 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
US20200071773A1 (en) 2017-04-12 2020-03-05 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
JP7355650B2 (en) 2017-04-14 2023-10-03 ジュノー セラピューティクス インコーポレイテッド Methods for assessing cell surface glycosylation
MX2019011897A (en) 2017-04-18 2019-11-28 Fujifilm Cellular Dynamics Inc Antigen-specific immune effector cells.
US20210293783A1 (en) 2017-04-18 2021-09-23 The General Hospital Corporation Compositions for detecting secretion and methods of use
BR112019022356A2 (en) 2017-04-27 2020-05-26 Juno Therapeutics Gmbh OLIGOMERIC PARTICLE REAGENTS AND METHODS OF USE THEREOF
IL310031A (en) 2017-05-01 2024-03-01 Juno Therapeutics Inc Combination of a cell therapy and an immunomodulatory compound
WO2018209324A2 (en) 2017-05-11 2018-11-15 The Broad Institute, Inc. Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
EP3625342B1 (en) 2017-05-18 2022-08-24 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
WO2018218038A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
EP3630132A1 (en) 2017-06-02 2020-04-08 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
US11740231B2 (en) 2017-06-02 2023-08-29 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
US11897953B2 (en) 2017-06-14 2024-02-13 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
AU2018287042A1 (en) 2017-06-20 2020-02-06 Centre National De La Recherche Scientifique - Cnrs - Immune cells defective for Suv39h1
KR20200019231A (en) 2017-06-22 2020-02-21 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Method for producing regulatory immune cells and uses thereof
US20220225597A1 (en) 2017-06-29 2022-07-21 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
MX2020000900A (en) 2017-07-29 2021-01-08 Juno Therapeutics Inc REAGENTS FOR EXPANDING CELLS EXPRESSING RECOMBINANT RECEPTORS.
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
SG11202000612TA (en) 2017-08-03 2020-02-27 Taiga Biotechnologies Inc Methods and compositions for the treatment of melanoma
CN111246862B (en) 2017-08-09 2026-01-13 朱诺治疗学股份有限公司 Methods of producing genetically engineered cell compositions and related compositions
AU2018313952B2 (en) 2017-08-09 2025-07-10 Juno Therapeutics, Inc. Methods and compositions for preparing genetically engineered cells
EP3676403A1 (en) 2017-09-01 2020-07-08 Juno Therapeutics, Inc. Gene expression and assessment of risk of developing toxicity following cell therapy
WO2019051335A1 (en) 2017-09-07 2019-03-14 Juno Therapeutics, Inc. Methods of identifying cellular attributes related to outcomes associated with cell therapy
CN109517820B (en) 2017-09-20 2021-09-24 北京宇繁生物科技有限公司 A gRNA targeting HPK1 and an HPK1 gene editing method
WO2019060746A1 (en) 2017-09-21 2019-03-28 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
US12043870B2 (en) 2017-10-02 2024-07-23 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
KR20200104284A (en) 2017-10-03 2020-09-03 주노 쎄러퓨티크스 인코퍼레이티드 HPV-specific binding molecule
CN111433222B (en) 2017-10-12 2025-01-28 得克萨斯大学体系董事会 T cell receptors for immunotherapy
WO2019084055A1 (en) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology Calling genetic variation from single-cell transcriptomes
PL3704230T3 (en) 2017-11-01 2025-02-24 Juno Therapeutics, Inc. PROCESS OF MANUFACTURING THERAPEUTIC COMPOSITIONS FROM GENETICALLY MODIFIED CELLS
MX2020004239A (en) 2017-11-01 2020-09-09 Juno Therapeutics Inc Process for producing a t cell composition.
BR112020008478A2 (en) 2017-11-01 2020-10-20 Editas Medicine, Inc. methods, compositions and components for editing crispr-cas9 of tgfbr2 in t cells for immunota-rapy
WO2019090003A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
KR20200074997A (en) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 Antibodies and chimeric antigen receptors specific for B-cell maturation antigens
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
CN111556893A (en) 2017-11-06 2020-08-18 爱迪塔斯医药股份有限公司 Methods, compositions, and components for CRISPR-CAS9 editing of CBLB in immunotherapy T cells
KR20200099137A (en) 2017-11-06 2020-08-21 주노 쎄러퓨티크스 인코퍼레이티드 Combination of cell therapy and gamma secretase inhibitor
CN111556789A (en) 2017-11-10 2020-08-18 朱诺治疗学股份有限公司 Closed System Cryogenic Vessels
WO2019094955A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
MA51210A (en) 2017-12-01 2020-10-07 Juno Therapeutics Inc METHODS FOR DOSING AND MODULATING GENETICALLY MODIFIED CELLS
BR112020011144A2 (en) 2017-12-08 2020-11-17 Juno Therapeutics Inc formulation of serum-free medium for cell culture and methods of using it
KR20250136416A (en) 2017-12-08 2025-09-16 주노 쎄러퓨티크스 인코퍼레이티드 Process for producing a composition of engineered t cells
BR112020011223A2 (en) 2017-12-08 2020-11-17 Juno Therapeutics Inc phenotypic markers for cell therapy and related methods
EP3723810A4 (en) * 2017-12-13 2022-02-23 Inovio Pharmaceuticals, Inc. ANTI-MESOTHELIN CANCER VACCINES AND THEIR USES
KR20200110745A (en) 2017-12-15 2020-09-25 주노 쎄러퓨티크스 인코퍼레이티드 Anti-CCT5 binding molecule and method of use thereof
TW201930340A (en) 2017-12-18 2019-08-01 美商尼恩醫療公司 Neoantigens and uses thereof
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
US11919937B2 (en) 2018-01-09 2024-03-05 Board Of Regents, The University Of Texas System T cell receptors for immunotherapy
CA3089319A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
KR20200128014A (en) 2018-01-31 2020-11-11 셀진 코포레이션 Adoptive cell therapy and combination therapy with checkpoint inhibitors
US11535903B2 (en) 2018-01-31 2022-12-27 Juno Therapeutics, Inc. Methods and reagents for assessing the presence or absence of replication competent virus
TW202000229A (en) 2018-02-23 2020-01-01 美商安德賽特公司 Sequencing method for CAR T cell therapy
US20210046159A1 (en) 2018-03-09 2021-02-18 Ospedale San Raffaele S.R.L. Il-1 antagonist and toxicity induced by cell therapy
AU2019247200A1 (en) 2018-04-05 2020-10-15 Editas Medicine, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
CN112566698A (en) 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T cell receptor and engineered cells expressing the same
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
CN112584902A (en) 2018-05-03 2021-03-30 朱诺治疗学股份有限公司 Combination therapy of Chimeric Antigen Receptor (CAR) T cell therapy and kinase inhibitors
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
TW202015719A (en) 2018-06-19 2020-05-01 美商尼恩醫療公司 New antigens and their uses
IL280659B2 (en) 2018-08-09 2024-11-01 Juno Therapeutics Inc Processes for creating transgenic cells and their compounds
WO2020033916A1 (en) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for assessing integrated nucleic acids
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
US12391685B2 (en) 2018-08-20 2025-08-19 The Broad Institute, Inc. Inhibitors of RNA-guided nuclease target binding and uses thereof
US12460244B2 (en) 2018-08-20 2025-11-04 The Broad Institute, Inc. Inhibitors of RNA-guided nuclease activity and uses thereof
JP7504891B2 (en) 2018-09-11 2024-06-24 ジュノー セラピューティクス インコーポレイテッド Methods for mass spectrometric analysis of engineered cell compositions - Patents.com
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
AU2019370705B2 (en) 2018-10-31 2026-01-22 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
ES2968737T3 (en) 2018-11-06 2024-05-13 Juno Therapeutics Inc Process to produce genetically engineered T cells
MX2021005366A (en) 2018-11-08 2021-09-10 Juno Therapeutics Inc Methods and combinations for treatment and t cell modulation.
CA3120118A1 (en) 2018-11-16 2020-05-22 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
EP3883955A1 (en) 2018-11-19 2021-09-29 Board of Regents, The University of Texas System A modular, polycistronic vector for car and tcr transduction
CN113272427A (en) 2018-11-28 2021-08-17 得克萨斯大学体系董事会 Multiple genome editing of immune cells to enhance functionality and resistance to suppressive environments
CN113316455A (en) 2018-11-29 2021-08-27 得克萨斯大学体系董事会 Method for ex vivo expansion of natural killer cells and use thereof
AU2019387497A1 (en) 2018-11-30 2021-06-24 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
US20220031746A1 (en) 2018-11-30 2022-02-03 Juno Therapeutics, Inc. Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
CA3124457A1 (en) 2018-12-21 2020-06-25 Biontech Us Inc. Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
KR20210122272A (en) 2019-01-29 2021-10-08 주노 쎄러퓨티크스 인코퍼레이티드 Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase-like orphan receptor 1 (ROR1)
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
US20220142948A1 (en) 2019-03-18 2022-05-12 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
EP3952909A4 (en) 2019-04-08 2023-06-07 Taiga Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR CRYOPRESERVATION OF IMMUNE CELLS
CN114025788A (en) 2019-05-01 2022-02-08 朱诺治疗学股份有限公司 Cells, related polynucleotides and methods for expressing recombinant receptors from modified TGFBR2 loci
CN114007640A (en) 2019-05-01 2022-02-01 朱诺治疗学股份有限公司 Cells expressing chimeric receptors from modified CD247 loci, related polynucleotides and methods
CA3137031A1 (en) 2019-05-14 2020-11-19 Yosef Refaeli Compositions and methods for treating t cell exhaustion
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
AU2020287882A1 (en) 2019-06-07 2022-01-20 Juno Therapeutics, Inc. Automated T cell culture
AU2020293230A1 (en) 2019-06-12 2022-01-27 Juno Therapeutics, Inc. Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival BCL2 family protein
CN114222815A (en) 2019-07-23 2022-03-22 记忆疗法公司 SUV39H1 deficient immune cells
US12480958B2 (en) * 2019-08-13 2025-11-25 Immatics Biotechnologies Gmbh Method for the characterization of peptide:MHC binding polypeptides
US20220282333A1 (en) 2019-08-13 2022-09-08 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
WO2021035194A1 (en) 2019-08-22 2021-02-25 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
WO2021041994A2 (en) 2019-08-30 2021-03-04 Juno Therapeutics, Inc. Machine learning methods for classifying cells
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
MX2022002578A (en) 2019-09-02 2022-06-02 Inst Curie Immunotherapy targeting tumor neoantigenic peptides.
CN114729368A (en) 2019-09-09 2022-07-08 斯克里贝治疗公司 Compositions and methods for immunotherapy
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
EP4048304A1 (en) 2019-10-22 2022-08-31 Institut Curie Immunotherapy targeting tumor neoantigenic peptides
WO2021084050A1 (en) 2019-10-30 2021-05-06 Juno Therapeutics Gmbh Cell selection and/or stimulation devices and methods of use
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
AU2020379043A1 (en) 2019-11-07 2022-06-02 Juno Therapeutics, Inc. Combination of a T cell therapy and (S)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-piperidine-2,6-dione
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
KR20220122656A (en) 2019-12-06 2022-09-02 주노 쎄러퓨티크스 인코퍼레이티드 Anti-idiotypic Antibodies and Related Compositions and Methods Against GPDAC5D-Targeting Binding Domain
CA3163897A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
US20230053787A1 (en) 2019-12-06 2023-02-23 Juno Therapeutics, Inc. Methods related to toxicity and response associated with cell therapy for treating b cell malignancies
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
WO2021151008A1 (en) 2020-01-24 2021-07-29 Juno Therapuetics, Inc. Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
KR20220146480A (en) 2020-01-28 2022-11-01 주노 쎄러퓨티크스 인코퍼레이티드 T cell transduction method
MX2022009830A (en) 2020-02-12 2022-10-28 Juno Therapeutics Inc Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof.
CN115768443A (en) 2020-02-12 2023-03-07 朱诺治疗学股份有限公司 CD19-directed chimeric antigen receptor T cell composition and method and use thereof
CA3168337A1 (en) 2020-02-17 2021-08-26 Marie-Andree Forget Methods for expansion of tumor infiltrating lymphocytes and use thereof
CA3179800A1 (en) 2020-04-10 2021-10-14 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021228999A1 (en) 2020-05-12 2021-11-18 Institut Curie Neoantigenic epitopes associated with sf3b1 mutations
EP4150057A2 (en) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Process for producing donor-batched cells expressing a recombinant receptor
US20230178239A1 (en) 2020-05-13 2023-06-08 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
JP2023526416A (en) 2020-05-21 2023-06-21 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム T cell receptor with VGLL1 specificity and methods of use thereof
JP2023531531A (en) 2020-06-26 2023-07-24 ジュノ セラピューティクス ゲーエムベーハー Engineered T Cells Conditionally Expressing Recombinant Receptors, Related Polynucleotides, and Methods
KR20230074713A (en) 2020-07-30 2023-05-31 엥스띠뛰 퀴리 Immune cells defective in SOCS1
KR20230095918A (en) 2020-08-05 2023-06-29 주노 쎄러퓨티크스 인코퍼레이티드 Anti-idiotype antibodies to the ROR1-target binding domain and related compositions and methods
JP2023538647A (en) 2020-08-21 2023-09-08 １２３４３０９６ カナダ インク． Modular assembly receptors and their uses
CN114106144B (en) * 2020-08-27 2024-01-26 溧阳瑅赛生物医药有限公司 TCR for identifying HLA-A 02/WT1 target and application thereof
WO2022087458A1 (en) 2020-10-23 2022-04-28 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
IL302728A (en) 2020-11-13 2023-07-01 Catamaran Bio Inc Genetically modified natural killer cells and methods of using them
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
TW202242121A (en) 2021-01-11 2022-11-01 美商薩那生物科技公司 Use of cd8-targeted viral vectors
US20240150711A1 (en) 2021-03-01 2024-05-09 Dana-Farber Cancer Institute, Inc. Personalized redirection and reprogramming of t cells for precise targeting of tumors
WO2022187406A1 (en) 2021-03-03 2022-09-09 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
JP2024510982A (en) 2021-03-11 2024-03-12 ムネモ・セラピューティクス tumor neoantigen peptide
EP4304634A1 (en) 2021-03-11 2024-01-17 Institut Curie Transmembrane neoantigenic peptides
KR20230172047A (en) 2021-03-11 2023-12-21 므네모 테라퓨틱스 Tumor neoantigen peptides and uses thereof
CN117321200A (en) 2021-03-22 2023-12-29 朱诺治疗学股份有限公司 Methods to assess viral vector particle potency
CA3210581A1 (en) 2021-03-22 2022-09-29 Neil HAIG Methods of determining potency of a therapeutic cell composition
WO2022212384A1 (en) 2021-03-29 2022-10-06 Juno Therapeutics, Inc. Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma
WO2022212400A1 (en) 2021-03-29 2022-10-06 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
JP2024514942A (en) 2021-04-22 2024-04-03 ベイラー カレッジ オブ メディスン Methods for engineering immune cells with reduced anti-contaminant activity
CN117916256A (en) 2021-05-06 2024-04-19 朱诺治疗学有限公司 Methods for stimulating and transducing T cells
WO2023014922A1 (en) 2021-08-04 2023-02-09 The Regents Of The University Of Colorado, A Body Corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
TW202321457A (en) 2021-08-04 2023-06-01 美商薩那生物科技公司 Use of cd4-targeted viral vectors
US20250354167A1 (en) 2021-12-09 2025-11-20 Zygosity Limited Vector
EP4448549A2 (en) 2021-12-17 2024-10-23 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
TW202342757A (en) 2021-12-17 2023-11-01 美商薩那生物科技公司 Modified paramyxoviridae attachment glycoproteins
JP2025501272A (en) 2021-12-28 2025-01-17 ムネモ・セラピューティクス Immune cells with inactivated SUV39H1 and modified TCR
US20250115916A1 (en) 2022-01-21 2025-04-10 Mnemo Therapeutics Modulation of suv39h1 expression by rnas
KR20240137075A (en) 2022-01-28 2024-09-19 주노 쎄러퓨티크스 인코퍼레이티드 Method for preparing a cell composition
US20250152709A1 (en) 2022-02-01 2025-05-15 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
CA3245554A1 (en) 2022-03-18 2023-09-21 The Regents Of The University Of Colorado, A Body Corporate Genetically engineered t-cell co-receptors and methods of use thereof
CA3254182A1 (en) 2022-03-24 2023-09-28 Universite Paris Cite Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US20250304913A1 (en) 2022-04-06 2025-10-02 The Regents Of The University Of Colorado, A Body Corporate Chimeric antigen receptor t cells and methods of use thereof
WO2023196921A1 (en) 2022-04-06 2023-10-12 The Regents Of The University Of Colorado, A Body Corporate Granzyme expressing t cells and methods of use
US20250235478A1 (en) 2022-04-28 2025-07-24 Musc Foundation For Research Development Chimeric antigen receptor modified regulatory t cells for treating cancer
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
KR20250029137A (en) 2022-06-22 2025-03-04 주노 쎄러퓨티크스 인코퍼레이티드 Treatment methods for second-line therapy with CD19-targeted CAR T cells
US20250382640A1 (en) 2022-06-29 2025-12-18 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids
KR20250084921A (en) 2022-08-26 2025-06-11 주노 쎄러퓨티크스 인코퍼레이티드 Antibodies and chimeric antigen receptors specific for Delta-like ligand 3 (DLL3)
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
EP4598949A1 (en) 2022-10-07 2025-08-13 The General Hospital Corporation Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
EP4602174A1 (en) 2022-10-13 2025-08-20 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
WO2024161021A1 (en) 2023-02-03 2024-08-08 Juno Therapeutics Gmbh Methods for non-viral manufacturing of engineered immune cells
IL322815A (en) 2023-02-28 2025-10-01 Juno Therapeutics Inc Cell therapy for treating systemic autoimmune diseases
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state
WO2024220588A1 (en) 2023-04-18 2024-10-24 Juno Therapeutics, Inc. Cytotoxicity assay for assessing potency of therapeutic cell compositions
WO2024220598A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Lentiviral vectors with two or more genomes
WO2024220560A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Engineered protein g fusogens and related lipid particles and methods thereof
WO2024220574A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
WO2024226838A2 (en) 2023-04-25 2024-10-31 The Brigham And Women's Hospital, Inc. Treatment of autoimmune diseases having a pathogenic t cell state
WO2024226858A1 (en) 2023-04-26 2024-10-31 Juno Therapeutics, Inc. Methods for viral vector manufacturing
WO2024243365A2 (en) 2023-05-23 2024-11-28 Juno Therapeutics, Inc. Activation markers of t cells and method for assessing t cell activation
WO2025054202A1 (en) 2023-09-05 2025-03-13 Sana Biotechnology, Inc. Method of screening a sample comprising a transgene with a unique barcode
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025082603A1 (en) 2023-10-18 2025-04-24 Institut Curie Engineered immune cells overexpressing cd74 molecule
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025096975A1 (en) 2023-11-02 2025-05-08 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of enhancing immune cell therapies by runx2 modulation
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses
US20250230470A1 (en) 2024-01-12 2025-07-17 Sana Biotechnology, Inc. Safety switches to control in vitro and in vivo proliferation of cell therapy products
WO2025163107A1 (en) 2024-02-01 2025-08-07 Institut Gustave Roussy Immune cells defective for znf217 and uses thereof
WO2025184421A1 (en) 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
US20250345431A1 (en) 2024-05-10 2025-11-13 Juno Therapeutics, Inc. Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
US6541249B2 (en) 1999-12-22 2003-04-01 Human Genome Sciences, Inc. Immortalized human stromal cell lines
EP1118661A1 (en) 2000-01-13 2001-07-25 Het Nederlands Kanker Instituut T cell receptor libraries
WO2003046141A2 (en) * 2001-11-26 2003-06-05 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
US7575925B2 (en) 2002-12-10 2009-08-18 Sunnybrook Health Sciences Centre Cell preparations comprising cells of the T cell lineage and methods of making and using them
GB0511124D0 (en) 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
EP1891209A1 (en) 2005-06-06 2008-02-27 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for generating a t cell against an antigen of interest.
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
WO2009097140A1 (en) * 2008-01-30 2009-08-06 Memorial Sloan-Kettering Cancer Center Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors
DK2352756T3 (en) 2008-11-24 2012-12-03 Helmholtz Zentrum Muenchen High-affinity T cell receptor and its use

Also Published As

Publication number Publication date
AU2013256159A1 (en) 2014-11-13
US10875904B2 (en) 2020-12-29
AU2018260963A1 (en) 2018-11-29
ES2858248T3 (en) 2021-09-29
KR102276888B1 (en) 2021-07-14
PH12014502418A1 (en) 2015-01-12
JP2015521172A (en) 2015-07-27
CA2872471C (en) 2022-11-22
CN104395462A (en) 2015-03-04
WO2013166321A1 (en) 2013-11-07
HK1208050A1 (en) 2016-02-19
RU2018130123A (en) 2018-11-07
CN104395462B (en) 2017-09-26
US9751928B2 (en) 2017-09-05
US20150118208A1 (en) 2015-04-30
KR20210013284A (en) 2021-02-03
SG10201609210SA (en) 2016-12-29
BR112014027374A2 (en) 2017-06-27
MX2014013270A (en) 2015-02-05
RU2014148286A (en) 2016-06-20
MX361760B (en) 2018-12-17
CN107557334A (en) 2018-01-09
JP6251734B2 (en) 2017-12-27
RU2665548C2 (en) 2018-08-30
CA2872471A1 (en) 2013-11-07
PH12014502418B1 (en) 2020-06-05
EP2844743B1 (en) 2021-01-13
IL235355A0 (en) 2014-12-31
EP2844743A1 (en) 2015-03-11
EP2844743A4 (en) 2015-12-30
CN107557334B (en) 2021-06-25
JP2018042564A (en) 2018-03-22
US20170362298A1 (en) 2017-12-21
SG11201407175RA (en) 2014-12-30
JP6666323B2 (en) 2020-03-13
IL235355B (en) 2019-10-31
AU2013256159B2 (en) 2018-08-09
AU2018260963B2 (en) 2021-04-29
BR112014027374B1 (en) 2022-05-31
NZ702108A (en) 2016-09-30
KR20150009556A (en) 2015-01-26
RU2018130123A3 (en) 2022-04-12

Similar Documents

Publication Publication Date Title
IN2014DN09787A (en)
MX2025010485A (en) Vcar compositions and methods for use
ZA202206078B (en) Anti-cd3 antibodies and methods of use
MX2019003427A (en) Cell culture compositions and methods for polypeptide production.
MX2019000643A (en) Chimeric antigen receptors and methods for use.
MX2021006932A (en) Engineered high-affinity human t cell receptors.
ZA201905470B (en) Method for generating t cells progenitors
MX358472B (en) CHEMICAL ANTIGEN RECEIVER EXPRESSION VECTOR (CAR) AND T-CELLS THAT EXPRESS CAR.
MY169317A (en) Methods for converting lignocellulosic material to useful products
HK1208233A1 (en) Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
MX2019014654A (en) Fgfr1 agonists and methods of use.
IN2014MN01879A (en)
SG10201810723VA (en) Improved t cell compositions
EP4292600A3 (en) Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
MY178142A (en) Anti-phf-tau antibodies and their uses
EP4438734A3 (en) Reprogramming of cells to a new fate
MX352881B (en) Methods and compounds useful in the synthesis of orexin-2 receptor antagonists.
SG10201809452RA (en) Cell culture compositions with antioxidants and methods for polypeptide production
MX2015011781A (en) Cell culture media and methods of antibody production.
EP4295914A3 (en) Genetically-engineered drug resistant t cells and methods of using the same
WO2015175534A3 (en) Compositions and methods employing stem cell-derived cardiomyocytes
BR112016021395A8 (en) methods of generating a pluripotent cell and preparing a test cell or tissue, using a pluripotent cell, and composition
GB201020671D0 (en) Passive immunotherapy
NZ740775A (en) Enhanced affinity t cell receptors and methods for making the same
WO2011094389A3 (en) Cxcr4 antagonists for imaging of cancer and inflammatory disorders